408 results
Page 14 of 21
6-K
EX-99.1
ysy3 r1i9gkod2c
20 Apr 12
Teva Announces Pricing of EUR 1 Billion and CHF 450 Million of Senior Notes, and the Closing of a New JPY 100 Billion Unsecured Syndicated Facility
12:00am
6-K
EX-99.1
te4li1uwh
18 Apr 12
Teva Announces New Data on Central Nervous System Products to Be Presented at 2012 American Academy of Neurology Annual Meeting
12:00am
6-K
EX-99.1
gtjzwxzd1
5 Apr 12
Live Filing
12:00am
6-K
EX-99.1
bguznsm32x cee
4 Apr 12
Teva Provides Litigation Update
12:00am
6-K
EX-99.1
h2fxv va7
28 Mar 12
Teva Announces Launch of Generic Seroquel® in the United States
12:00am
6-K
EX-99.1
r5x470
21 Mar 12
Live Filing
12:00am
6-K
EX-99.1
b515eh5ap zqm7clw
16 Mar 12
Live Filing
12:00am
6-K
EX-99.1
hjghr
14 Mar 12
Teva Announces Launch of Generic Lexapro® in the United States; Awarded 180-Day Period of Marketing Exclusivity
12:00am
6-K
EX-99.1
seqfjnv jj7f
8 Mar 12
Teva Receives FDA Approval for ProAir® HFA (albuterol sulfate) with Dose Counter
12:00am
6-K
EX-99.1
2xy 4s3knv98ks4b
8 Mar 12
Teva and OncoGenex Announce Updates to Custirsen Development Program in Advanced Prostate Cancer
12:00am
6-K
EX-99.1
0mi7zni1k90
5 Mar 12
Late Stage Data Demonstrated Long-Term Nasal Symptom Relief and Improvement in Quality of Life
12:00am
6-K
EX-99.1
rdl 3lonm8d3vxt
2 Mar 12
Teva Announces Launch of Generic Prometrium® Capsules in the United States
12:00am
6-K
r491 auk5uw9k5d
15 Feb 12
Teva Pharmaceutical Industries Limited 6-K
12:00am
6-K
EX-99.1
fgkditp4
3 Jan 12
Teva Announces Management Succession
12:00am
6-K
EX-99.1
vnppwy7q7
3 Jan 12
Live Filing
12:00am
6-K
EX-99.1
c621 bck4b3tl7sutp
21 Dec 11
Teva Provides 2012 Non-GAAP Financial Outlook; 2012 Non-GAAP Diluted EPS of $5.48 to $5.68
12:00am
F-3ASR
01oyg2m npsfu
9 Dec 11
Automatic shelf registration (foreign)
12:00am
6-K
EX-99.1
lqsymhl3yo7xraeck
2 Dec 11
Live Filing
12:00am
6-K
EX-99.1
v7ho8v0y95u
1 Dec 11
Live Filing
12:00am